The U.S. Food and Drug Administration reported major oncology updates in March 2026, highlighting advances in precision treatment and imaging. For advanced Hodgkin lymphoma, Nivolumab plus AVD is now approved as first-line therapy, improving outcomes over older regimens. In ovarian cancer, Relacorilant with chemotherapy was approved for platinum-resistant disease, cutting the risk of death by 35%. PNT2003 also received tentative approval for certain neuroendocrine tumors.
Diagnostic progress includes approval of a new version of Piflufolastat F 18 for prostate cancer imaging, offering better availability. The MyChoice® CDx test is now the only approved tool to identify patients eligible for Niraparib in ovarian cancer.
Several drugs are under accelerated review, including Trastuzumab deruxtecan for early breast cancer and lirafugratinib for cholangiocarcinoma. Additional updates include orphan drug status for ChemoSeed in high-grade glioma and the resubmission of Anktiva plus BCG for bladder cancer.